SG Americas Securities LLC Sells 23,950 Shares of Mineralys Therapeutics, Inc. $MLYS

SG Americas Securities LLC lowered its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 19.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 100,037 shares of the company’s stock after selling 23,950 shares during the quarter. SG Americas Securities LLC owned approximately 0.15% of Mineralys Therapeutics worth $3,793,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Mineralys Therapeutics by 51.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in shares of Mineralys Therapeutics by 42.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after buying an additional 1,197 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Mineralys Therapeutics during the 2nd quarter worth approximately $91,000. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Mineralys Therapeutics by 29.4% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,234 shares of the company’s stock worth $125,000 after acquiring an additional 2,098 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in shares of Mineralys Therapeutics during the 2nd quarter worth approximately $141,000. 84.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Brian Taylor Slingsby sold 1,000,000 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $43.35, for a total transaction of $43,350,000.00. Following the sale, the director owned 7,903,838 shares of the company’s stock, valued at $342,631,377.30. This represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Alexander M. Gold sold 12,742 shares of Mineralys Therapeutics stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $46.50, for a total value of $592,503.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,642,320 shares of company stock valued at $69,775,277 in the last quarter. Company insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $33.37 on Monday. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $47.65. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -11.31 and a beta of 0.49. The firm’s 50-day simple moving average is $39.00 and its 200 day simple moving average is $30.62.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.14. Sell-side analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wells Fargo & Company lifted their price objective on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. HC Wainwright lifted their target price on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Finally, Stifel Nicolaus raised their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $47.43.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.